Actithera develops next-generation radioligand therapies by linking radioactive isotopes to precisely designed molecules for targeted cancer treatment. Their proprietary chemistry ensures prolonged tumor retention and minimized off-target effects on healthy tissues. This approach aims to deliver effective treatment with fewer cycles, enhancing patient quality of life.

Alex Therapeutics develops AI-integrated digital therapy companions that assist patients in managing complex treatment regimens and mental health challenges associated with cancer and rare diseases. Their evidence-based platform enhances patient adherence to medication and therapy, leading to improved health outcomes through behavior modification.

AntagomiR develops anti-miR oligonucleotides targeting upregulated microRNAs in myotonic dystrophy patients, addressing the underlying toxic DMPK and insufficient MBNL levels. Their fatty acid-conjugated delivery system enables effective treatment with a significantly reduced active dose directly to muscle tissue.

CardioMech develops a catheter-based device that utilizes artificial chords to reduce mitral regurgitation, a condition characterized by the backward flow of blood across the mitral valve. This technology offers a less invasive alternative to open-heart surgery for patients with structural heart disease, potentially improving outcomes and reducing recovery times.

Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.

EUM provides a residential management platform that utilizes AI-driven tools for efficient defect reporting and maintenance coordination, enabling residents to easily register issues through voice recognition and QR code scanning. The service connects residents with property managers, ensuring timely repairs and enhancing overall living quality in newly constructed apartments.

Gen+ is a digital platform that provides leadership and meta-skills education for learners aged 9-14 and their teachers, utilizing a blended learning approach that combines online and in-person instruction. The program addresses the lack of standardized skills development in schools by equipping students with essential, transferable skills necessary for success in learning, work, and life.

Inven utilizes AI algorithms to analyze extensive data from various sources, enabling professionals in private equity, investment banking, and management consulting to identify high-potential companies and acquisition targets quickly. This technology significantly reduces the time spent on manual research, allowing users to source deals and gain market insights more efficiently.

The startup develops an artificial intelligence-powered diagnostic software that utilizes video and sensor data, combined with computer vision and machine learning, to monitor and analyze epilepsy seizures. This platform provides neurologists and patients with critical insights into seizure patterns, enhancing treatment decisions and patient care.

Ribbon Biolabs utilizes algorithm-driven technology to synthesize pristine synthetic DNA molecules, producing linear DNA up to 12 kb and plasmids up to 20 kb with high accuracy and complexity. This addresses the critical demand for longer and more complex synthetic DNA that existing technologies fail to deliver, enabling advancements in various sectors of synthetic biology.

SAGA Diagnostics specializes in molecular residual disease (MRD) detection using a proprietary platform that combines next-generation sequencing and digital PCR to create patient-specific genetic fingerprints from tumor samples. This technology enables ultra-sensitive monitoring of residual cancer post-treatment, facilitating timely and informed therapeutic decisions through simple blood draws.

SciRhom GmbH develops first-in-class humanized antibodies targeting iRhom2 to selectively inhibit TACE, a key enzyme involved in pro-inflammatory signaling pathways associated with autoimmune diseases. This approach aims to provide effective treatments for conditions such as rheumatoid arthritis and inflammatory bowel disease without the severe side effects linked to traditional TACE inhibitors.

Develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor targeting blood cancers and solid tumors, including ovarian cancer. This therapy aims to improve treatment outcomes by selectively inhibiting CTPS1 in patients with cancers that have lost CTPS2 expression, addressing the lack of effective options and stagnant survival rates in conditions like peripheral T cell lymphoma.

TargED Biopharmaceuticals develops TGD001, a targeted thrombolytic therapy utilizing small antibodies for localized enzyme delivery to effectively treat various forms of thrombosis. This approach aims to enhance thrombolysis in patients suffering from conditions such as Immune Thrombotic Thrombocytopenic Purpura and Acute Ischemic Stroke, addressing a significant global health issue that contributes to over 16 million deaths annually.